BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Nov 08, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

QLT091001: Phase Ib amended

QLT amended an ongoing, open-label, Canadian Phase Ib trial of QLT091001 to include patients with retinitis pigmentosa (RP) and subsequently increased enrollment to up to 24 from up to 8....

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >